<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489160</url>
  </required_header>
  <id_info>
    <org_study_id>NL7255105823</org_study_id>
    <nct_id>NCT04489160</nct_id>
  </id_info>
  <brief_title>Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic Brain Injury</brief_title>
  <acronym>CIAO@TBI</acronym>
  <official_title>A Phase II Trial on the Safety and Efficacy of C1 Inhibitor for the Acute Management of Severe Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Netherlands Brain Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe Traumatic Brain Injury (s-TBI) is a major cause of death and disability across all
      ages. Besides the primary impact, the pathophysiologic process of major secondary brain
      damage consists of a neuroinflammation response that critically leads to irreversible brain
      damage in the first days after the trauma. A key catalyst in this inflammatory process is the
      complement system. Inhibiting the complement system is therefore considered to be a
      potentially important new treatment for TBI, as has been shown in animal studies. This trial
      aims to study the safety and efficacy of C1-inhibitor compared to placebo in TBI patients. By
      temporarily blocking the complement system we hypothesize limitation of secondary brain
      injury and more favourable clinical outcome for TBI patients due to a decrease in the
      posttraumatic neuroinflammatory response.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapy Intensity Level (TIL) Scale</measure>
    <time_frame>First four ICU days</time_frame>
    <description>TIL differentiated for various treatment modalities aimed at prevention or control of raised Intracranial Pressure (ICP) and/or for CPP management (0 to 38 points)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glasgow Outcome Scale Extended (GOSE)</measure>
    <time_frame>At 6 months after trauma</time_frame>
    <description>Functional outcome (minimum score = 1, maximum score = 8)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complication rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Adverse and serious adverse events related possibly related to study medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intracranial pressure (ICP) burden</measure>
    <time_frame>First four ICU days</time_frame>
    <description>Minutes of ICP&gt;20 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT scan midline shift</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 1 year after trauma</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Outcome Scale Extended (GOSE)</measure>
    <time_frame>At discharge (an average of 14 days), 3 and 12 months after trauma</time_frame>
    <description>Functional outcome (minimum score = 1, maximum score = 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoLiBri</measure>
    <time_frame>At 3, 6 and 12 months after trauma</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>At 3, 6 and 12 months after trauma</time_frame>
    <description>Health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L</measure>
    <time_frame>At 6 and 12 months after trauma</time_frame>
    <description>Health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator days</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital disposition</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Discharged to home, rehabilitation or nursery home</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UCH-L1 and GFAP biomarkers</measure>
    <time_frame>Baseline (Before adminstration of investigational product ) and 6, 12, 24, 48, 72 and 96 hours after adminstration of investigational product</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement activation</measure>
    <time_frame>Baseline (Before adminstration of investigational product ) and 6, 12, 24, 48, 72 and 96 hours after adminstration of investigational product</time_frame>
    <description>WIESLAB, C3b/C, C4b/C, C5b-9 ELISA assays, CH50/AC50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation cascade activation</measure>
    <time_frame>Baseline (Before adminstration of investigational product ) and 6, 12, 24, 48, 72 and 96 hours after adminstration of investigational product</time_frame>
    <description>PT, aPPT, PLT, D-dimer, fibrinogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Baseline (Before adminstration of investigational product ) and 6, 12, 24, 48, 72 and 96 hours after adminstration of investigational product</time_frame>
    <description>TNF-alpha, intraleukins</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <condition>Trauma, Head</condition>
  <arm_group>
    <arm_group_label>C1-inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose 6000 IU C1-inhibitor intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C1 Inhibitor, Human</intervention_name>
    <description>6000 IU C1-INH</description>
    <arm_group_label>C1-inhibitor</arm_group_label>
    <other_name>Cinryze</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at admission â‰¥ 18 years and &lt; 65 years;

          -  Clinical diagnosis of traumatic brain injury with GCS &lt; 13 (with intracranial
             deviations);

          -  Catheter placement for monitoring and management of increased ICP for at least 24
             hours;

        Exclusion Criteria:

          -  A clear, non-traumatic cause of low GCS (e.g. toxic, cardial) on admission;

          -  Not expected to survive more than 24 hours after admission;

          -  Brain death on arrival in the participating centers;

          -  Severe pre-trauma disability, defined as being dependent on other people;

          -  Known prior history of sensibility to blood products or Cinryze;

          -  Patients with a history of hereditary angioedema;

          -  Patients with a history of thrombosis;

          -  Pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilco Peul, MD, MPH, PhD, MBa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inge van Erp, BSc</last_name>
    <phone>+31(0)715262109</phone>
    <email>i.a.m.van_erp@lumc.nl</email>
  </overall_contact>
  <reference>
    <citation>Fluiter K, Opperhuizen AL, Morgan BP, Baas F, Ramaglia V. Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice. J Immunol. 2014 Mar 1;192(5):2339-48. doi: 10.4049/jimmunol.1302793. Epub 2014 Jan 31.</citation>
    <PMID>24489093</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>wcpeul</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>C1-inhibitor</keyword>
  <keyword>Neuroinflammation</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Craniocerebral Trauma</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

